Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 2,018.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,097,096 shares of the company's stock after acquiring an additional 1,045,305 shares during the period. Allspring Global Investments Holdings LLC owned about 0.10% of Teva Pharmaceutical Industries worth $23,368,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Stifel Financial Corp increased its holdings in shares of Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after acquiring an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after purchasing an additional 33,277 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Teva Pharmaceutical Industries by 21.8% in the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company's stock valued at $4,046,000 after purchasing an additional 40,218 shares during the last quarter. Sio Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth approximately $24,314,000. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $3,340,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded up $0.62 during trading on Wednesday, hitting $17.19. The company had a trading volume of 12,950,584 shares, compared to its average volume of 13,069,499. The firm has a 50-day moving average price of $19.93 and a 200-day moving average price of $18.50. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a market cap of $19.47 billion, a PE ratio of -11.85, a price-to-earnings-growth ratio of 1.31 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.55% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TEVA has been the topic of several research analyst reports. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Finally, Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.